Diversifying R&D Risk Through Multiple Products Under Development
First written in FY2016. 16 of 30 entries say "Restated". Latest entry: 2026-08-13.
The whole theme swung hardest in 2024: 2 of 6 companies on the "Worse" side.
2 other companies' latest entry also says "Restated".
- FY2026ReframedAnnual report
「Particularly in the cell therapy business, in light of its business characteristics, including the front-loading of R&D investment, we are redefining cerebral palsy as the highest-priority indication and shifting to a policy of strategically concentrating management resources in this area.」
In the cell therapy business, the policy has shifted from the conventional approach of advancing multiple development candidates in parallel to redefining cerebral palsy as the highest-priority indication and concentrating management resources on it. - FY2026-H1AdvancedAnnual report
「In May 2025, we and Chiome entered into a Master Service Agreement with MBI concerning the development of novel biosimilars. At MBI, construction of cell lines for multiple novel biosimilars, which had been under selection for some time, has begun.」
For multiple novel biosimilars, development progressed to the stage of beginning cell-line construction following the execution of agreements with Chiome and MBI. - FY2025RestatedAnnual report
「Our Group has multiple development candidates in both businesses. To deploy our limited management resources efficiently and generate maximum results, we are working to maximize the value of each development candidate through collaboration with partner pharmaceutical companies and other entities, as well as outsourced service providers.」
The company is reaffirming its policy of optimizing its development portfolio by maintaining multiple development candidates, collaborating with partners, reviewing priorities and deciding when to discontinue development. - FY2025-H1ReframedAnnual report
「In addition, we are prioritizing our multiple R&D pipeline candidates based on factors such as development progress and commercial viability, while pursuing sustained growth and optimizing R&D investment.」
In addition to the conventional approach of diversifying risk by maintaining multiple pipeline candidates, the focus is shifting toward operations that optimize R&D investment through prioritization based on development progress and commercial viability. - FY2024-Q3AdvancedAnnual report
「In addition, GBS-010, a pegfilgrastim biosimilar that we had been jointly developing with Mochida Pharmaceutical Co.,Ltd. since December 2016 as the fourth biosimilar following the 3 products described above, obtained marketing approval in September 2023, and sales began in November of the same year.」
Regarding the fourth product, GBS-010 progressed to the launch stage, obtaining approval in September 2023 followed by the start of sales in November of the same year. - FY2024-Q2AdvancedAnnual report
「In addition, GBS-010, a pegfilgrastim biosimilar that we have been jointly developing with Mochida Pharmaceutical Co.,Ltd. since December 2016 as the fourth biosimilar following the 3 products described above, obtained marketing approval in September 2023. Sales are scheduled to begin by the end of 2023.」
The fourth product, GBS-010, progressed from the stage of continued development and a planned launch to obtaining marketing approval in September 2023. - FY2024-Q1AdvancedAnnual report
「In addition, development of the fourth biosimilar following the 3 products described above is progressing steadily, with a launch scheduled for sometime in 2023.」
The fourth product under development has progressed from continued development to the stage of a planned launch in 2023. - FY2023-Q3RestatedAnnual report
「We are also steadily advancing development activities for pipelines currently under development, including the fourth product, which is intended to be launched after the 3 products described above.」
We continue to advance the development pipeline, including the fourth product following the existing 3 products. - FY2023-Q2RestatedAnnual report
「We are also steadily advancing development activities for pipelines currently under development.」
We are continuing to advance multiple pipelines under development. - FY2023-Q1RestatedAnnual report
「We are also steadily advancing development activities for pipelines currently under development.」
We are reaffirming the policy of continuing to advance multiple development pipelines. - FY2022-Q3RestatedAnnual report
「We are also steadily advancing development activities for pipelines currently under development.」
We are reaffirming that we are continuing to advance multiple pipelines under development. - FY2022-Q1AdvancedAnnual report
「Among these, clear efficacy of SHED against diseases has been confirmed in preclinical studies for numerous pipelines, and we are steadily progressing toward out-licensing.」
The disclosure states that clear efficacy was confirmed in preclinical studies for numerous SHED-based pipelines and that progress is being made toward out-licensing. - FY2021-Q3RestatedAnnual report
「We are also steadily advancing development activities for pipelines currently under development.」
We are reaffirming our efforts to diversify R&D risk by continuing to advance our existing multiple development pipelines. - FY2021-Q2AdvancedAnnual report
「Also in August, we entered into a three-party joint research agreement with Hokkaido University and the 総合せき損センター for the development of a treatment for intractable fractures using dental pulp stem cells.」
We entered into a joint research agreement with Hokkaido University and the 総合せき損センター for a treatment for intractable fractures using dental pulp stem cells, resulting in tangible expansion of the R&D pipeline. - FY2021-Q1RestatedAnnual report
「We are also steadily advancing development activities for pipelines currently under development.」
We continue efforts to diversify R&D risk by maintaining and advancing multiple development pipelines. - FY2020AdvancedAnnual report
「For dental pulp stem cells, we assessed their suitability for treating diseases, and multiple academic institutions and companies evaluated their potential to provide new treatments in fields such as bone and neurological diseases, leading to the expansion of our pipeline.」
Joint research agreements with multiple academic institutions and companies resulted in tangible expansion of the development pipeline for bone, neurological and other diseases using dental pulp stem cells. - FY2020-Q3AdvancedAnnual report
「In December 2019, we entered into a joint development agreement with 癸巳化成㈱ for an aflibercept biosimilar to expand our biosimilars business and began development.」
There was tangible progress in diversifying risk and expanding the pipeline through multiple development products, with the start of joint development of an aflibercept biosimilar. - FY2019RestatedAnnual report
「We believe that the most important priority for diversifying R&D risk is to hold multiple development products and strengthen the pipeline.」
We are reaffirming the diversification of R&D risk through multiple development products and a strengthened pipeline as our most important priority. - FY2019-Q1RestatedAnnual report
「⑤ Expansion of development products for other multiple biosimilars」
We are reaffirming the policy of expanding the number of multiple biosimilars under development and diversifying R&D risk. - FY2018RestatedAnnual report
「We are diversifying R&D risk and expanding revenue opportunities by maintaining a pipeline containing multiple development products in each of the biosimilars and biologics new drugs business areas and adding a new biologics business in the future.」
We are reaffirming the policy of diversifying R&D risk and expanding revenue opportunities through multiple development products and a new biologics business. - FY2018-Q3RestatedAnnual report
「⑥ Expansion of development products for other multiple biosimilars」
We are reaffirming the policy of expanding the number of multiple biosimilars under development and broadening the pipeline. - FY2017RestatedAnnual report
「We are diversifying R&D risk and expanding revenue opportunities by maintaining a pipeline containing multiple development products in each of the biosimilars and biologics new drugs business areas and adding a new biologics business in the future.」
We continue to pursue the policy of diversifying R&D risk and expanding revenue opportunities through multiple biosimilars and biologics new drugs and a future new biologics business. - FY2017-Q3RestatedAnnual report
「We believe that the most important priority for diversifying risk in pharmaceutical development is to hold multiple development products and strengthen the pipeline.」
We continue to regard as our top priority the policy of diversifying R&D risk by holding multiple development products and strengthening the pipeline. - FY2017-Q2RestatedAnnual report
「We believe that the most important priority for diversifying risk in pharmaceutical development is to hold multiple development products and strengthen the pipeline.」
We are reaffirming as our top priority the policy of diversifying R&D risk by holding multiple development products and strengthening the pipeline. - FY2017-Q1RestatedAnnual report
「We believe that the most important priority for diversifying risk in pharmaceutical development is to hold multiple development products and strengthen the pipeline.」
We continue to regard diversifying R&D risk through multiple development products as our most important priority. - FY2016First statedAnnual report
「We are diversifying R&D risk by maintaining a pipeline containing multiple development products in each of the biosimilars and biologics new drugs business areas.」
We intend to maintain multiple biosimilars and biologics new drugs in parallel and reduce dependence on individual development products.